Cutting-edge Research to Create Better Solutions for Prostate Cancer

April 15, 2024 Providence News Team

Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.

We are one of only a few dozen hospitals in the world and just three in California—along with City of Hope and UCSF—to offer Phase I trials of this first-in-class antibody capable of targeting prostate cancer cells.

The AMG 509 antibody binds to two different proteins, one commonly found on the surface of prostate cancer cells and one on the immune system’s T cells. “AMG 509 triggers an activation of the patient’s T cells and redirects them to cluster on and eradicate cancer cells,” explains Yung Lyou, MD, a Crosson Cancer Institute genitourinary oncologist who specializes in prostate, kidney and bladder cancers.

Men with metastatic prostate cancer who have not responded to or have refused a taxane regimen are currently being enrolled.

To learn more about any of the research trials currently underway for a wide range of cancers, please call our oncology research department at 714-446-5177.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

Cutting-edge Research to Create Better Solutions for Prostate Cancer

About the Author

Previous Article

Next Article

Cutting-edge Research to Create Better Solutions for Prostate Cancer

About the Author

Previous Article

Next Article

Other content in this Stream

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Learn about dysautonomia, its symptoms, and how it's connected to long COVID. Discover treatment options and expert insights at Providence.

A research collaboration between CORE, PSU researcher Dr. Roberta Hunte and the Healthy Birth Initiative (HBI), is studying the impact of a cross-sector partnership on Black maternal health outcomes.

A novel peptide vaccine against glioblastoma, a deadly brain tumor, is offering hope to some patients thanks to the work of an international effort including Providence's Santosh Kesari, MD, PhD.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

The procedure using the new TriClip to repair a leaky tricuspid valve was also a first in the Pacific Northwest.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A first-of-its-kind study on the efficacy and safety of weight loss medications in the real world is helping to provide clinicians with new is helping to provide clinicians with valuable new evidence.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.

Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report

Learn more about a clinical trial for men with metastatic prostate cancer.

In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.